top of page


IPAC-RS has launched a Roundtable webinar series on digital devices for 2021.  Presented by subject matter experts in the pharmaceutical sciences, this is a unique opportunity to learn about the latest research and regulatory trends focused on digital devices.  

The second webinar in the series, Beyond Usability/Human Factors for Digital Healthcare is scheduled for Tuesday, September 21, 2021 from 10:00 AM – 12:00 PM US ET.  



  • Marta Lombardini, Ph.D., Device Development Manager, Chiesi Group

  • Fredrik Mannerstråle, Director Regulatory CMC, Medical Devices and Combination Products, AstraZeneca 



  • Haydyn Phillips, User Experience (UX) lead, AstraZeneca

  • Ian Culverhouse, Ph.D., Co-Founder, Rebus Medical Ltd.

Webinar Program and Abstracts:

I.     Welcome and Overview of Webinar

  • Moderators:  Marta Lombardini and Fredrik Mannerstråle


II.     HF Synergies, Integrating UX, Behavioural Science and Digital Health

  • Haydyn Phillips, AstraZeneca


The continuous safe development of digital health outputs has provided opportunity to both individuals and organisations through HFE. However, more is needed if we are to push beyond just usable and safe products. Both the practice of User Experience and applied behavioural science give us the opportunity to gain deep, targeted understanding for our target populations and provide different perspectives when it comes to both research and design, especially in digital health outcomes. This outline will provide some thoughts and examples of how teams can come together to work with these elements and drive better outcomes in the HFE space.

III.     Evolution of HF Test Methods for Digital Healthcare Systems

  • Ian Culverhouse, Rebus Medical Ltd.


Drawing on  15 years industry experience, the presentation will examine the rise of the digital healthcare market and the increasingly important role Human Factors Engineering has to play in it. Whilst much progress has been made in the past decade to integrate HFE within medical device and combination drug product development, the presentation identifies three areas where HF could further evolve test methods to address specific requirements associated with digital healthcare.  

IV.     Moderated Q&A Session with the speakers

Click to view Speaker Bios.  Feel free to share the registration information with interested colleagues.

bottom of page